Physician profile
Sandeep Singh
NPI 1245277490
$2,869.24
in general payments reported to CMS, 2019-2025
15 companies · $67.74 in 2025
The $67.74 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,184 · 2021: $102 · 2022: $127 · 2023: $212 · 2024: $176 · 2025: $67.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $431 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $431.34 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $2,080.20 | 2019 | |
| Nxstage Medical, INC. | $165.62 | 2022-2023 | Nxstage System One, Liberty Select Cycler |
| Novartis Pharmaceuticals Corporation | $98.44 | 2024 | |
| Horizon Therapeutics Plc | $95.68 | 2022-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $94.28 | 2019-2021 | |
| Glaxosmithkline, LLC. | $86.79 | 2021-2022 | |
| Amgen INC. | $80.26 | 2024-2025 | Krystexxa |
| Aurinia Pharma U.S., INC. | $43.69 | 2021-2022 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Calliditas Therapeutics US INC. | $22.32 | 2025 | Tarpeyo |
| Janssen Pharmaceuticals, INC | $18.26 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.12 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $17.44 | 2023 | |
| Esperion Therapeutics, INC. | $12.01 | 2021 | |
| Fresenius USA Marketing, INC. | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.